Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20; 27(27):4462-8.

View in: PubMed

collapse authors with profiles